Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Albrecht, Philipp, Bjørnå, Ingrid Kristine, Brassat, David, Farrell, Rachel, Feys, Peter, Hobart, Jeremy, Hupperts, Raymond, Linnebank, Michael, Magdič, Jožef, Oreja-Guevara, Celia, Pozzilli, Carlo, Salgado, Antonio Vasco, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174649/
https://www.ncbi.nlm.nih.gov/pubmed/30305850
http://dx.doi.org/10.1177/1756286418803248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174649/
https://www.ncbi.nlm.nih.gov/pubmed/30305850
http://dx.doi.org/10.1177/1756286418803248

Ejemplares similares